NYSE:NVTA Invitae (NVTA) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free NVTA Stock Alerts $0.01 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.0105▼$0.012050-Day Range$0.01▼$0.4552-Week Range$0.02▼$0.02Volume2.64 million shsAverage Volume23.72 million shsMarket Capitalization$2.94 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Invitae alerts: Email Address Invitae MarketRank™ Stock AnalysisAnalyst RatingStrong Sell1.00 Rating ScoreUpside/Downside8,990.9% Upside$1.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.12 out of 5 stars 2.5 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Strong Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Invitae has a forecasted upside of 8,990.9% from its current price of $0.01.Amount of Analyst CoverageInvitae has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NVTA. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 71.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.13. Previous Next 2.0 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search InterestOnly 7 people have searched for NVTA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows13 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of Invitae is held by insiders.Percentage Held by Institutions61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.05) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Invitae Stock (NYSE:NVTA)Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More NVTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTA Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comInvitae (NYSE:NVTA) Coverage Initiated by Analysts at StockNews.comMarch 12, 2024 | finance.yahoo.comInvitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant ClassificationMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 11, 2024 | reuters.comNVTA.PKMarch 9, 2024 | reuters.comNVTA.NMarch 6, 2024 | finanznachrichten.deInvitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | prnewswire.comInvitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | prnewswire.comInvitae to Present Data at the 2024 ACMG Annual Clinical Genetics MeetingMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 3, 2024 | finance.yahoo.comNVTA Jun 2024 0.500 putFebruary 26, 2024 | finance.yahoo.comNVTA Jan 2026 1.500 callFebruary 17, 2024 | finance.yahoo.comNVTA Mar 2024 0.500 putFebruary 15, 2024 | msn.comInvitae gets court approval for five-month bankruptcy saleFebruary 15, 2024 | bizjournals.comGenetic testing pioneer Invitae files for bankruptcy protectionFebruary 14, 2024 | msn.comGenetic Test Provider Invitae (OTC:NVTA) Files for BankruptcyFebruary 14, 2024 | msn.comGenetic test maker Invitae files for bankruptcy protection in USFebruary 14, 2024 | finance.yahoo.comInvitae Files for Voluntary Chapter 11 Protection; Pursues Sale ProcessFebruary 13, 2024 | reuters.comGenetic test maker Invitae files for bankruptcy protection in USFebruary 13, 2024 | prnewswire.comInvitae Files for Voluntary Chapter 11 Protection; Pursues Sale ProcessFebruary 9, 2024 | edition.cnn.comInvitae Corp.February 6, 2024 | investorplace.comNVTA Stock: Invitae Plunges 78% on the Brink of BankruptcyFebruary 6, 2024 | finance.yahoo.comNYSE to Commence Delisting Proceedings Against Invitae Corporation (NVTA)February 6, 2024 | finanznachrichten.deInvitae Corporation: Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsFebruary 5, 2024 | investorplace.comWhy Is Invitae (NVTA) Stock Down 75% Today?February 5, 2024 | reuters.comMedical test maker Invitae prepares for bankruptcy - WSJFebruary 5, 2024 | msn.comInvitae plunges amid report it may file for bankruptcy within weeksJanuary 30, 2024 | finance.yahoo.comInvitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsSee More Headlines Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.50 Low Stock Price Target$0.50 Potential Upside/Downside+8,990.9%Consensus RatingStrong Sell Rating Score (0-4)1.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-299.14% Pretax Margin-301.93% Return on Equity-6,100.71% Return on Assets-19.68% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.25 Sales & Book Value Annual Sales$481.58 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.03Miscellaneous Outstanding Shares267,010,000Free Float284,373,000Market Cap$2.94 million OptionableOptionable Beta1.59 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Randal W. Scott Ph.D. (Age 66)Co-Founder & Chairman of the Board Comp: $50kMr. Kenneth D. Knight (Age 63)President, CEO & Director Comp: $1.4MMr. Thomas R. Brida (Age 53)General Counsel, Chief Compliance Officer & Secretary Comp: $776.72kMs. Ana J. Schrank (Age 58)Chief Accounting Officer & CFO Dr. David B. Sholehvar M.D. (Age 56)Chief Operating Officer Ms. Hoki Luk (Age 48)Head of Investor Relations and Capital Markets Ms. Shelly D. Guyer (Age 64)Chief Sustainability Officer Comp: $430.44kMs. Desarie FrenchChief Talent OfficerDr. W. Michael Korn M.D.Chief Medical OfficerMr. Robert GuigleyChief Commercial OfficerMore ExecutivesKey CompetitorsOpGenNASDAQ:OPGNBioNexus Gene LabNASDAQ:BGLCPsychemedicsNASDAQ:PMDCentogeneNASDAQ:CNTGExicureNASDAQ:XCURView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,132,646 shares on 3/11/2024Ownership: 5.490%Vanguard Group Inc.Bought 1,132,646 shares on 2/15/2024Ownership: 5.117%Citadel Advisors LLCSold 18,500 shares on 2/15/2024Ownership: 0.000%GTS Securities LLCSold 700 shares on 2/15/2024Ownership: 0.000%HAP Trading LLCBought 14,500 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions NVTA Stock Analysis - Frequently Asked Questions Should I buy or sell Invitae stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 sell ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "strong sell" NVTA shares. View NVTA analyst ratings or view top-rated stocks. What is Invitae's stock price target for 2024? 3 equities research analysts have issued 1-year price objectives for Invitae's shares. Their NVTA share price targets range from $0.50 to $1.50. On average, they anticipate the company's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 8,990.9% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts. How have NVTA shares performed in 2024? Invitae's stock was trading at $0.6268 at the start of the year. Since then, NVTA shares have decreased by 98.2% and is now trading at $0.0110. View the best growth stocks for 2024 here. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) posted its earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.04. The medical research company had revenue of $117.36 million for the quarter, compared to the consensus estimate of $116.57 million. Invitae had a negative net margin of 299.14% and a negative trailing twelve-month return on equity of 6,100.71%. The company's revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.78) EPS. What ETFs hold Invitae's stock? ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), ARK Genomic Revolution ETF (ARKG) and Global X Genomics & Biotechnology ETF (GNOM).ARK Innovation ETF (ARKK). What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. Who are Invitae's major shareholders? Invitae's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.36%), Vanguard Group Inc. (5.12%), Vanguard Group Inc. (5.49%), UBS Group AG (0.41%), Goldman Sachs Group Inc. (0.37%) and State of Michigan Retirement System (0.34%). Insiders that own company stock include Artur Bergman, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen. View institutional ownership trends. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NVTA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.